台灣臨床試驗主持人資料庫|TPIDB

2018-11-02 - 2028-12-31

Phase III

Active

A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)

Condition/Disease

Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer
Test Drug

Durvalumab (MEDI4736)

Participate Sites
9Sites

Recruiting6Sites

Terminated3Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬

Taipei Medical University Hospital

Division of Thoracic Medicine

2017-04-01 - 2020-06-01

Phase III

Open-label extension study to evaluate the long-term safety and tolerability of dupilumab inpatients with asthma who participated in a previous dupilumab asthma clinical study

Condition/Disease

asthma
Test Drug

Dupilumab

Participate Sites
4Sites

Terminated3Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

鍾啟禮

Taipei Medical University Hospital

Division of Thoracic Medicine

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

Condition/Disease

Severe eosinophilic leukocyte asthma
Test Drug

Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬

Taipei Medical University Hospital

Division of Thoracic Medicine

2018-05-25 - 2028-12-31

Phase III

A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis

Condition/Disease

Rheumatoid Arthritis
Test Drug

Filgotinib

Participate Sites
10Sites

Recruiting1Sites

Terminated9Sites

方耀凡

Linkou Chang Gung Medical Foundation

張棋楨

Taipei Medical University Hospital

2018-11-01 - 2022-06-21

Phase III

A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) who Had an Inadequate Response or Intolerance to MTX

Condition/Disease

Rheumatoid Arthritis (RA)
Test Drug

ASP015K

Participate Sites
6Sites

Terminated5Sites

黃春明

China Medical University Hospital-Taipei

未分科

張棋楨

Taipei Medical University Hospital

2017-06-08 - 2019-04-30

Phase II

An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects with Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment

Condition/Disease

Squamous Cell Head and Neck Cancer
Test Drug

SCB01A

Participate Sites
4Sites

Terminated4Sites

張牧新

Taipei Veterans General Hospital

Division of Hematology & Oncology

夏和雄

Taipei Medical University Hospital

Division of Hematology & Oncology

2015-05-01 - 2017-03-25

Phase III

A randomized, double-blind, active drug-controlled, parallel grouping trial, in patients with severe to very severe chronic obstructive pulmonary disease (COPD), using tiotropium as a benchmark to evaluate oral inhaled tiotropium + olodaterol fixed-dose combination once a day The effect of 52-week treatment on the acute onset of COPD. [DYNAGITO]

Condition/Disease

COPD
Test Drug

Tiotropium + Olodaterol fixed dose combination (FDC) inhalation solution- RESPIMATR Inhaler

Participate Sites
15Sites

Terminated13Sites

鍾飲文

Kaohsiung Municipal Gangshan Hospital

未分科

鍾啟禮

Taipei Medical University Hospital

Division of Thoracic Medicine

Search Result

List